Commonwealth Equity Services LLC Sells 4,897 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Commonwealth Equity Services LLC reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 17.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,425 shares of the biopharmaceutical company’s stock after selling 4,897 shares during the period. Commonwealth Equity Services LLC’s holdings in Halozyme Therapeutics were worth $1,275,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Advisory Research Inc. grew its stake in shares of Halozyme Therapeutics by 6.6% during the third quarter. Advisory Research Inc. now owns 37,915 shares of the biopharmaceutical company’s stock valued at $1,499,000 after buying an additional 2,360 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 1.2% in the third quarter. ProShare Advisors LLC now owns 36,252 shares of the biopharmaceutical company’s stock worth $1,434,000 after purchasing an additional 423 shares during the last quarter. TD Asset Management Inc bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth approximately $10,406,000. Point72 Asset Management L.P. bought a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $12,014,000. Finally, Resources Investment Advisors LLC. grew its holdings in shares of Halozyme Therapeutics by 12.2% in the third quarter. Resources Investment Advisors LLC. now owns 6,466 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 701 shares during the last quarter. 96.32% of the stock is owned by institutional investors.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, April 18th. The stock was sold at an average price of $36.00, for a total value of $360,000.00. Following the sale, the senior vice president now directly owns 141,911 shares of the company’s stock, valued at $5,108,796. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 50,000 shares of company stock valued at $2,214,600. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $33.87 on Friday. The stock has a market cap of $4.46 billion, a PE ratio of 25.86, a price-to-earnings-growth ratio of 0.53 and a beta of 1.21. The company has a debt-to-equity ratio of 22.69, a quick ratio of 5.52 and a current ratio of 6.69. Halozyme Therapeutics, Inc. has a fifty-two week low of $29.85 and a fifty-two week high of $59.46. The firm’s 50-day simple moving average is $35.00 and its two-hundred day simple moving average is $46.34.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last announced its quarterly earnings data on Tuesday, February 21st. The biopharmaceutical company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.01. The business had revenue of $181.50 million for the quarter, compared to analysts’ expectations of $186.07 million. Halozyme Therapeutics had a net margin of 25.76% and a return on equity of 184.32%. Analysts anticipate that Halozyme Therapeutics, Inc. will post 2.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HALO has been the topic of several recent analyst reports. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $65.00 to $64.00 and set an “overweight” rating on the stock in a report on Monday, March 6th. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $65.00 to $55.00 and set an “overweight” rating on the stock in a research note on Thursday, March 16th. Berenberg Bank started coverage on Halozyme Therapeutics in a research note on Monday, March 27th. They issued a “buy” rating and a $58.00 target price on the stock. StockNews.com started coverage on shares of Halozyme Therapeutics in a report on Thursday. They issued a “hold” rating on the stock. Finally, SVB Leerink cut shares of Halozyme Therapeutics from an “outperform” rating to a “market perform” rating and set a $42.00 price target on the stock. in a report on Thursday, March 16th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $55.30.

Halozyme Therapeutics Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.